Provenance Record

Clear, well-structured News piece with appropriate Overview / What We Know / What We Don't Know / Analysis framing for a clinical-trial result. Technical depth (co-primary endpoints, SVR35, Abs-TSS, hazard ratio, confidence interval, immaturity of OS data) is handled accurately and accessibly. 898 words, within the News 400-1200 range.

All 3 source snapshots read from disk and verified. source-0.html.gz (Karyopharm/PR Newswire, ASCO, status 200): confirmed SVR35 49.8% vs 28.0% at week 24, odds ratio 2.58 (95% CI 1.60-4.17; p<0.0001); Abs-TSS adjusted mean difference 0.97 (95% CI -1.07 to 3.02; p=0.825) co-primary NOT met; OS HR 0.43 (95% CI 0.19-1.00; nominal one-sided p=0.022); 224/235 (95.3%) vs 106/118 (89.8%) alive as of February 20, 2026; N=353, randomized 2-to-1, 60 mg once-weekly, JAK-inhibitor-naive, platelets >100x10^9/L; XPORT-MF-034 / NCT04562389; TEAEs 99.1% vs 97.4%; thrombocytopenia 59% vs 43%, nausea 57% vs 17%, neutropenia 27% vs 9%; grade 3+ 70% vs 50%; TEAEs leading to death 0.9% vs 2.6%; confirmed leukemic transformation 1.7% each arm; June 2, 2026 late-breaking oral presentation; Mascarenhas quote and title verbatim. source-1.html.gz (Menarini Group/PR Newswire, EHA, status 200): confirmed arm sizes n=235 / n=118, SVR35 week 12 (49.4% vs 20.3%), week 24 (49.8% vs 28.0%), week 36 (46.9% vs 23.0%); symptom improvement 9.9 vs 10.9 points; HR 0.43, 'greater than 50% reduction in the risk of death'; 'No new safety signals were observed' verbatim; Harrison quote ('Achievement of spleen reduction is the essential goal of myelofibrosis treatment') and title verbatim; Ergun quote ('the strength of the spleen response and the encouraging early overall survival data observed in the SENTRY study creates hope for a potential new treatment option for patients suffering from this devastating disease with dismal outcomes') and title verbatim. source-2.html.gz (StockTitan, status 200): independently confirms the co-primary split — 'SENTRY met SVR35 endpoint with strong HR but missed symptom endpoint', 'hazard ratio of 0.43, but the symptom endpoint was not met', co-primary endpoints SVR35 and Abs-TSS over 24 weeks. Rule 9 check: the JCO primary publication is bot-blocked/not allowlisted and was correctly dropped from the source list; every numeric specific, quote, name, and date in the article is independently carried by the three accessible sources above and NONE rests on the JCO.

All claims align with the cited accessible sources. The split co-primary result is reported correctly: the trial MET the spleen-volume co-primary (SVR35) and MISSED the symptom co-primary (Abs-TSS, p=0.825). The overall survival signal (HR 0.43) is correctly framed throughout as a pre-specified secondary endpoint that is immature/suggestive rather than confirmatory, with the article explicitly noting the CI reaches up to 1.00 and the p-value is nominal and one-sided. No hallucinations detected.

Accurate, well-sourced, neutral clinical-trial report. Every specific is independently verified against the three accessible sources and none depends on the bot-blocked JCO publication. The split co-primary outcome and the immature OS signal are reported correctly. Approving with a minor clarification corrections record for the lone loaded-language warning.